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Abstract
Background: Commercially available assays to detect antibodies to the herpes simplex virus type
2 (HSV-2)-specific glycoprotein gG-2 have markedly improved serologic diagnosis of HSV-2
infection. However, even tests with high specificity can have low positive predictive values in low
prevalence populations. HSV-2 is a chronic, life-long viral infection that requires both medical
attention and potential alterations in health care strategy. As such, the concern for false positive
diagnoses is high confirmatory testing is routine for other viral serologies such as HIV and hepatitis
C. We evaluated such a strategy for HSV-2 serology by using an easily performed commercial test,
biokitHSV-2 rapid test ("Biokit"; Biokit USA, Lexington MA) as a confirmatory test for the widely
used gG-2 specific serology ("Focus;" HerpeSelect HSV-2 ELISA; Focus Diagnostics, Cypress CA).
Methods: We tested 782 sera by Focus HSV-2 ELISA, Biokit, and the current gold standard test,
Western blot (WB).
Results: The positive predictive value of the Focus HSV-2 ELISA increased from 80.5% to 95.6%
when Biokit testing was performed on sera that were initially positive by Focus HSV-2 ELISA.
Confirmatory testing increased the specificity markedly among sera with Focus EIA values between
1.1 and 3.5: only 35% of low positive (index values 1.1–3.5) Focus HSV-2 ELISA results confirmed
as positive by Biokit and WB compared with 92% of those with index values >3.5. Mathematical
modeling of the data resulted in expected positive predictive values over 98% for populations with
antibody prevalences typical of clinical practices in the US and Europe.
Conclusion: Confirmatory Biokit testing of positive Focus HSV-2 ELISA results is fast, easy, and
effective in reducing falsely positive HSV-2 antibody results. Patients, clinicians, and laboratories
could benefit from the enhanced specificity of this simple HSV-2 serologic test combination.
Background
Several studies over the last decade have shown the
importance of subclinical HSV-2 reactivation in the epide-
miology of HSV-2 infection. Over 95% of persons who are
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genital sites and 70% of sexual and maternal-fetal trans-
mission occurs from such subclinical shedding. As such,
serologic detection of past HSV-2 increasingly is being rec-
ommended for a variety of immunocompetent and
immunosuppressed populations. Several enzyme linked
immunoassays for HSV-1 and HSV-2 antibodies to the
type-specific glycoproteins, gG-1 and gG-2, respectively,
are approved by the U.S. Food and Drug Administration.
These methods are cost effective, widely available, and are
the only commercial methods that accurately differentiate
HSV-1 from HSV-2 antibodies. The HerpeSelect HSV-2
gG2 ELISA test (Focus Diagnostics) demonstrated a sensi-
tivity of 96% in a group of pregnant women and 95% in
an STD population of men and women [1]. Specificity of
Focus HSV-2 ELISA also was high in these groups: 97 % in
pregnant women and 96% in the STD population [1].
Both groups had relatively high HSV-2 seroprevalence by
Western blot (WB); 25% of the pregnant women and 22%
of the STD group had antibodies to HSV-2.
However, in select patient groups from several African
countries, the Focus HSV-2 ELISA may give falsely positive
results when compared with other gG-based tests such as
the gG-2 monoclonal antibody inhibition assay [2] or WB
[3,4]. A recent study of a low prevalence population sug-
gests that falsely positive tests may not be limited to Afri-
can populations [5]. All of these studies have found that
Focus HSV-2 ELISA false positive results are far more likely
with sera that have index values in the low positive range
(1.1–3.5) than those that have index values above 3.5
[4,6]. As such, a confirmatory test to improve test specifi-
city is desirable.
In 2000, a gG-2-based point of care membrane test,
POCkit-HSV-2, was cleared by the US Food and Drug
Administration for use with capillary blood and sera. This
test showed high sensitivity and specificity in premarket
trials against WB [7,8]. This test is now available as
"biokitHSV-2 Rapid Test" from Biokit USA or as "SureVue-
HSV-2" Rapid Test from Fisher HealthCare, Houston, TX.
The biokitHSV-2 Rapid Test ("Biokit") is a readily accessi-
ble alternative to WB for confirmatory testing and can be
performed easily on sera within a few minutes. Perform-
ing Biokit tests on sera that are initially positive by Focus
HSV-2 ELISA could provide a useful strategy to increase
the specificity of this HSV-2 serology.
To assess the value of biokit-HSV-2 as a confirmatory
assay after an initial screening by Focus HSV-2 ELISA, we
selected two sets of sera to study: 1) one from men at high
risk for genital herpes and 2) one from an all-comer group
of sera received by the University of Washington labora-
tory for HSV antibody testing. Biokit results were the same
as WB results in 93.7% of these sera. Concordance of WB
and Focus HSV-2 ELISA was 88.9%; concordance of Biokit
and Focus HSV-2 ELISA was 86.7%. Using the Biokit result
for sera positive by Focus HSV-2 ELISA increased the spe-
cificity from 93.2% to 98.7%. Positive predictive values
increased from 80.5% for Focus HSV-2 ELISA to 95.6%
when Biokit results were applied to sera that were positive
by Focus HSV-2 ELISA.
Methods
Serology
Focus HerpeSelect HSV-2 ELISA ("Focus HSV-2 ELISA";
Focus Diagnostics, Cypress CA) was performed on each
serum according to kit instructions. Sera with index values
<0.9 were considered negative, those >3.5 as positive, val-
ues .9–1.1 (inclusive) were considered equivocal. Index
values >1.1 to 3.5 were considered low positive.
The biokitHSV-2 Rapid Assay ("Biokit") Biokit USA, Lex-
ington, MA) was performed according to kit instructions.
Positive results were those in which the test spot was
clearly colored red or pink. Negative results were those
that had very faint or no color on the test spot. In a few
cases, a colored ring appeared around an uncolored spot.
These were scored negative.
The Western blot assay ("WB") for HSV-1 and HSV-2 was
performed as described previously [9].
Study subjects
Two groups were studied: 1) High-risk population:
Through Dec 1, 2004, 1125 adult "men who have sex with
men" (MSM) were tested by Focus HSV-2 ELISA to screen
for enrollment into a National Institutes of Health trial
evaluating acyclovir therapy to reduce acquisition of HIV-
1 infection among HSV-2 seropositive persons (HIV Pre-
vention Trial Network Protocol 039). As such, this serum
subset was biased toward men who felt they had previ-
ously acquired HSV-2. Of the 388 sera found to be posi-
tive by Focus HSV-2 ELISA, 301 (77.6%) had sufficient
volume to be used in the comparison study. Of the 718
that were seronegative by Focus HSV-2 ELISA, every 10th
sample with sufficient volume (N = 67) was selected to
test by Biokit and WB. Sera that were indeterminate by
Focus HSV-2 ELISA (N = 19) or WB (N = 14) were not
tested by Biokit.
2) All-comer sera: We also tested 624 consecutive sera sub-
mitted for HSV WB testing to the University of Washing-
ton Virology Laboratory during a 4 week period in 2004.
Of all subjects whose sera were received in 2004, 10%
were under 20 years of age; 86% were 21–60 years old and
3% were over 60 years of age. Thus, some of our sample
was likely to be pediatric. Of 148 sera that were positive
by Focus HSV-2 ELISA, 141 were used in the comparison
study. We selected 273 of the 469 samples that werePage 2 of 7
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that were equivocal by Focus HSV-2 ELISA (N = 6) or by
WB (N = 22) or by both tests (N = 1) were not analyzed
further.
Samples from both groups were stripped of identifiers
before performing the tests for this study. After de-identi-
fying, each serum was stored at -20C and was thawed once
for this study.
Statistical measures
All Focus positive and low positive samples with sufficient
volume were tested by WB and Biokit. Only a subset of
Focus negative sera were run by WB or Biokit. Therefore,
raw estimates of sensitivity, specificity and other predic-
tive values were expected to be biased [10]. To adjust for
this bias, we calculated expected confirmation rates
among unconfirmed Focus negative results and incorpo-
rated these hypothetical results. Estimation was per-
formed conservatively using binomial theory, first using
positive rates for WB and Biokit in confirmed data to com-
pute endpoints of a 95% confidence interval for the hypo-
thetical number confirmed positive, then applying the
extremes of this range to form two potential confidence
intervals for each accuracy measure. A maximally-wide
interval was built by combining these.
Results
HSV-2 prevalence of the study populations was between
23.7 and 34.5% by Focus HSV-2 ELISA (Table 1). Overall,
one-third of the HSV-2 seropositive sera had low positive
results.
Because we were interested in evaluating the ability of the
Biokit assay to serve as a confirmatory test for positive
Focus HSV-2 ELISA samples, all seropositive sera with suf-
ficient volume were used for subsequent WB and Biokit
testing. In particular, 142 (78.5%) of the 181 low positive
sera and 300 (84.5%) of the 355 high positive samples
were tested by WB and Biokit. A subset of 340 (28.6%) of
the 1187 seronegative sera by Focus HSV-2 ELISA was
tested further (Table 1).
Effect of index value on confirmation
The proportion of sera that was positive by Focus HSV-2
ELISA and either WB or Biokit rose from <12–15% of sera
with initial index values of 1.1–1.5 to >90% for index val-
ues >3.5 (Figure 1). The proportion of sera that confirmed
at each index value level was very similar between Biokit
and WB (Figure 1).
Table 1: HSV-2 status of study populations by Focus HSV-2 ELISA
Number of Sera (% of Group Total)
MSM Group All-Comer Group All Subjects
HSV-2 Status 
(Index value)
Population Sera Tested Population Sera Tested Population Sera Tested
Positive
(All >1.1) 388 (34.5) 301 148 (23.7) 141 536 442
(Only >3.5) 245 (21.8) 194 110 (17.6) 106 355 300
(Only 1.1 – 3.5) 143 (12.7) 107 38 (6.1) 35 181 142
Equivocal (.9 – 1.1) 19 (1.7) 0 7 (1.1) 0 26 0
Negative (<0.9) 718 (63.8) 67 469 (75.2) 273 1187 340
Total 1125 368 624 414 1749 782
Western blot and Biokit results sorted by Focus HSV-2 ELISA index valueFigure 1
Western blot and Biokit results sorted by Focus HSV-2 
ELISA index value. The proportion of sera that were positive 
by western blot (hatched bars) or by biokitHSV2 Rapid Test 
(solid bars) is shown for each range of index values obtained 
by Focus HerpeSelect HSV-2 ELISA. Numbers of sera (N) 
contributing to each subset are given below the designated 
index value ranges.
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The 3 tests had the same result in 662 (85%) of the 782
study sera (Figure 2) with 337 sera having concordantly
negative results and 325 sera having concordantly positive
results. Focus HSV-2 ELISA and WB were concordant in
339 negative sera and in 356 positive sera; overall 695
(88.9%). Focus HSV-2 ELISA and Biokit were concordant
in 338 negative and 340 positive results; overall 678
(86.7%). WB and Biokit were concordant in 408 negative
and 325 positive results for an overall concordance of
93.7%.
Of 300 sera that were positive by Focus HSV-2 ELISA with
index values over 3.5, 275 (92%) confirmed by both
Biokit and WB. Fifteen results confirmed as positive by
WB, only (Figure 2). Low positive (index values 1.1–3.5)
index values occurred in 142 sera. Only 50 (35.2%) con-
firmed as positive by both Biokit and WB while 62
(43.7%) confirmed by neither test (Figure 2). The low
positive Focus HSV-2 ELISA index value group yielded the
majority (N = 30) of the study's 49 discordant sera
between Biokit and WB. Sera that were negative for HSV-
2 antibody by Focus HSV-2 ELISA were nearly always neg-
ative by WB (339; 99.7%) or Biokit (338; 99.4%).
Effect of Biokit confirmatory testing on test accuracy
To compute test accuracy, we applied data from the 340
sera that were seronegative by Focus HSV-2 ELISA to those
Focus negative sera that were not run by WB or Biokit. We
determined that approximately 2 (confidence interval
[CI] 0–7) of the additional 847 seronegative sera would
be positive by WB and about 5 (CI 0–12) would be posi-
tive by Biokit. Specificity of the Focus test was, in this way,
estimated to be 93.2 (CI 91.8–94.6) with WB results as the
gold standard. Specificity of the Biokit test, alone, against
WB, was 98.4 (CI 97.5–99.3) (Table 2). Use of Biokit test-
ing on all Focus HSV-2 ELISA positive sera improved esti-
mated specificity from 93.2 to 98.7% without sacrificing
sensitivity (99.1%). Positive predictive value improved
HSV-2 serology results by HerpeSelect HSV-2 ELISA ("Focus"), biokitHSV2 Rapid Test ("Biokit") and western blot (WB) in 782 seraFigure 2
HSV-2 serology results by HerpeSelect HSV-2 ELISA ("Focus"), biokitHSV2 Rapid Test ("Biokit") and western blot (WB) in 782 
sera.
Focus HSV-2 ELISA 
< 0.9 (negative) ? 1.1, < 3.5 (low positive) ? 3.5 (positive) 
 n=340 n=142 n=300
 Biokit Biokit Biokit
 Negative Positive Negative Positive Negative Positive
 n=338 n=2 n=78 n=64 n=24 n=276
 WB WB WB WB WB WB
Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos 
n=337 n=1 n=2 n=0 n=62 n=16 n=14 n=50 n=9 n=15 n=1 n=275 Page 4 of 7
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remained at 99.7% (Table 2).
Effect of HSV-1 antibody on discordance for HSV-2 
between tests
Seventeen sera were false positive by Biokit as compared
with WB. Two were also negative by Focus HSV-2 ELISA;
14 were low positive by Focus HSV-2 ELISA and 1 was
positive by Focus HSV-2 ELISA with an index value >3.5.
All 17 were positive for HSV-1 antibody by WB.
Of 86 sera with positive Focus test results but negative WB
results, 68 (79.1%) were positive for HSV-1. The overall
HSV-1 prevalence in the study was 64% (502 of 782) by
WB. Thus, Biokit, and to a lesser extent, Focus HSV-2
ELISA specificity values appeared to be affected by the
presence of HSV-1 antibodies. Conversely, WB could be
falsely negative for HSV-2 in the presence of HSV-1
antibody.
Predictive value of the test algorithm by population 
prevalence
We used the data for estimated sensitivity and specificity
to evaluate the positive and negative predictive values that
would be expected with populations that differ in preva-
lence of HSV-2 infection. As shown in Table 3, the use of
the Biokit test to confirm initial Focus HSV-2 ELISA posi-
tive results (i.e. considering only results that are positive
by both Focus HSV-2 ELISA and Biokit to be true posi-
tives) enhanced the positive predictive value (PPV) in all
populations. PPV increased with increasing prevalence as
predicted by Bayes theorem (PPV = Θp/ [Θp + (1-Φ)(1-
p)], where p = prevalence, Θ = test sensitivity, and Φ = test
specificity). For example, in groups with very low HSV-2
prevalence (10%) the PPV increased from 61.9 to 89.8%.
For prevalences typical of antenatal practices (30%) and
STD clinics (40–50%), the PPV of the test combination
was over 97% and 98%, respectively.
Discussion
Commercially available type specific serologic testing for
HSV-2 has markedly improved the ability to diagnose this
common, widespread infection with significant clinical
and therapeutic implications. While these assays have
been extremely useful for research and epidemiological
studies, there has been concern about their specificity for
case management of HSV-2, especially in populations in
which definitive data on seroprevalence are lacking [5].
Sera that have index values between 1.1 and 3.5 by Focus
HSV-2 ELISA have the highest probability of being falsely
positive. In our study, over one third of positive sera fell
into this category of "low positive" index values and the
majority of these sera did not confirm as positive by the
Western blot assay (WB) [6].
One approach to this problem is to perform confirmatory
assays on sera initially positive in the screening test. For
example, the HerpeSelect immunblot assay is easy to run,
relatively inexpensive at about $25 per test, and is FDA
approved. However, the test is based on the same gG-2
antigen as the Focus HSV-2 ELISA and performs almost
identically with that test [1]. As such, the immunoblot test
has not been highly effective in discriminating falsely
positive from truly positive Focus HSV-2 ELISA results [5].
Other confirmatory testing options require shipping sera
to a reference laboratory for western blot (WB) or
inhibition ELISAs that, while effective [6], can be time-
consuming and expensive. We selected the biokit HSV-2
Rapid HSV-2 Test ("Biokit") as a confirmatory test because
it is relatively inexpensive (about $20 per test), requires
less than 10 minutes and no special equipment to per-
form, is FDA approved, and can be purchased and easily
performed by any laboratory. The gG-2 antigen is a lectin-
purified native protein as compared with the recombinant
gG-2 used by Focus. Biokit's test also differs in presenting
the antigen within a membrane while, in the Focus test,
the gG-2 is sterically bound to a plastic microwell. These
differences may result in different subpopulations of anti-
bodies being detected so that a positive result in both tests
is a more rigorous result than one provided by a single
test.
Our study demonstrated that sera in the "low positive"
index value range (1.1–3.5) by Focus HSV-2 ELISA had
Table 2: Estimated sensitivity and specificity of HSV-2 tests
Focus Biokit Focus Plus Biokit
Sensitivity 99.2 (96.3,100.0) 90.5 (86.1,94.0) 99.1 (96,100.0)
Specificity 93.2 (91.8,94.6) 98.4 (97.5,99.3) 98.7 (98.1,99.4)
Positive Predictive Value 80.5 (76.9,84.2) 94.5 (90.5,97.3) 95.6 (93.4,97.8)
Negative Predictive Value 99.7 (98.9,100.0) 97.5 (96.6,98.4) 99.7 (98.9,100.0)
Ranges indicated show the confidence intervals for accuracy; these also incorporate the uncertainty from having confirmed only a portion of Focus 
negatives. Biokit was used to confirm all sera that were initially positive for HSV-2 antibodies by Focus HSV-2 ELISA; the combined test results are 
shown in the "Focus Plus Biokit" column.Page 5 of 7
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tests: Focus, Biokit, and WB. Only 35.2% of low positive
sera were positive by all 3 tests. In contrast, 99% of the
Focus HSV-2 ELISA-negative sera were concordantly nega-
tive by all 3 tests and 92% of 300 sera with index values
>3.5 were concordantly positive by all 3 tests. Low posi-
tive results are not rare. In the high risk MSM group in our
study, 12.7% of sera, overall, and 36.9% of positive sera
had index values of 1.1–3.5. In the all-comer group, 6.1%
of sera, overall, and 25.7% of positive sera had low posi-
tive index values.
When sera with positive Focus HSV-2 ELISA results were
run by Biokit, the combination provided a confirmed pos-
itive result in 340 (76.9%) of the 442 sera. By comparison,
WB confirmed 356 (80.5%) of positive results. Moreover,
71 (16%) of the 442 positive sera were negative by both
Biokit and WB; thus additional testing successfully identi-
fied false positive results in a significant proportion of the
study population (4.1%). Overall, 89.6% of positive sera
were given a higher quality answer as defined by confirm-
ing a positive result or by identifying a false positive.
Either of these testing outcomes would serve to enhance
the confidence of the laboratory providing results or the
clinician preparing to counsel a patient.
The few false positive results from our testing strategy were
all seen among those who were HSV-1 seropositive, a
finding that has been previously described in a different
patient population [5]. Several explanations are possible:
First, the WB, which was the comparator assay, could be
falsely negative; HSV-2 antibodies are more difficult to
detect against a background of HSV-1 antibodies. Second,
cross-reactive epitopes on glycoprotein G may affect the
tests. While glycoprotein G molecules from HSV-1 and
HSV-2 are predominantly distinct immunologically, there
are regions of sequence homology and this effect cannot
be definitively ruled out [11,12].
The two-step testing algorithm resulted in an increase in
indeterminate results as defined by a positive Focus HSV-
2 ELISA and a negative Biokit test. When Focus HSV-2
ELISA, alone, is used, 1% (26 of 1749) of study sera had
index values in the indeterminate or "equivocal" range
(0.9–1.1). When Biokit confirmatory testing was done,
the additional unconfirmed results led to a total of 7.3%
(128 of 1749) of samples with indeterminate outcomes.
We feel this is a reasonable tradeoff for higher accuracy in
determining HSV-2 infection status. Most of these addi-
tional indeterminate sera (N = 78) were low positive and
most (N = 71) did not confirm by WB.
Several options are reasonable to determine HSV-2
serostatus in patients with Focus HSV-2 ELISA positive
results that fail to confirm by Biokit. First, laboratories
might consider retesting by Focus HSV-2 ELISA to rule out
Table 3: Positive and negative predictive values of HSV-2 test approaches by population prevalence
Positive Predictive Value
True Prevalence Focus HSV-2 ELISA Biokit Focus HSV-2 ELISA+Biokit
10 61.9% 86.5% 89.8%
20 78.5% 93.5% 95.2%
30 86.3% 96.1% 97.1%
40 90.7% 97.5% 98.1%
50 93.6% 98.3% 98.8%
70 97.2% 99.3% 99.5%
90 99.2% 99.8% 99.9%
Negative Predictive Value
10 99.9% 98.9% 99.9%
20 99.8% 97.7% 99.8%
30 99.6% 96.0% 99.6%
40 99.4% 94.0% 99.4%
50 99.1% 91.2% 99.1%
70 98.0% 81.7% 97.9%
90 92.5% 53.6% 92.3%
Ranges indicated show the confidence intervals for accuracy; these also incorporate the uncertainty from having confirmed only a portion of Focus 
negatives. Biokit was used to confirm all sera that were initially positive for HSV-2 antibodies by Focus HSV-2 ELISA; the combined test results are 
shown in the "Focus Plus Biokit" column.Page 6 of 7
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that low positive results can be artificially introduced by
splashing or by dipping the pipette tip into a positive
ELISA well, then into a negative well [4]. Seventy-four of
the 86 sera that were positive by Focus HSV-2 ELISA but
negative by WB were repeated and 11 sera (14.8%)
retested as negative; all 11 were negative by Biokit. Thus,
a repeat test can resolve the serostatus quickly, without
redrawing blood from the patient, and, ideally, before the
serology result leaves the laboratory. A second option is to
re-test the patient in 6–12 weeks to rule out early serocon-
version [13,14]. This option also applies to patients
whose first sample was repeatedly low positive. A third
option to establish HSV-2 serostatus is to send the sample
to a reference laboratory for WB or to Focus Diagnostics
for a gG-2 inhibition assay [6].
Conclusion
Our study shows that Biokit confirmation of positive
Focus results (index values >1.1) can substantially
improve the positive predictive value of serologic screen-
ing for HSV-2 antibodies by Focus HSV-2 ELISA. Clini-
cians who counsel and manage patients with suspected
herpes infections or asymptomatic, low-risk patients who
wish to be screened for herpes may consider confirmatory
testing to be both justified and cost-effective to increase
accuracy. Laboratories now have available a quick and
inexpensive means of providing a highly specific test com-
bination for HSV-2.
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